IMKELDI vs OFEV

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 22, 2026·How we rate

Possible drug interaction. IMKELDI and OFEV are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	IMKELDI	OFEV
Rating	New	72/100
Pharmacy pays	~$25.80 /30	—
Type	RX	RX
Active ingredient	IMATINIB MESYLATE	NINTEDANIB ESYLATE
Manufacturer	Shorla Oncology	Boehringer Ingelheim
Dosage forms	Solution	Capsule
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome	Idiopathic Pulmonary Fibrosis

imkeldi ofev

Rating

New

72/100

Pharmacy pays

~$25.80 /30

—

Type

Active ingredient

IMATINIB MESYLATE

NINTEDANIB ESYLATE

Manufacturer

Shorla Oncology

Boehringer Ingelheim

Dosage forms

Solution

Capsule

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Idiopathic Pulmonary Fibrosis

Frequently asked questions

What is the difference between Imkeldi and Ofev?

Imkeldi contains Imatinib Mesylate, while Ofev contains Nintedanib Esylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.